NAMPT Activator Compounds for Safer NAD+ Elevation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing strategies to boost NAD+ levels for treating various diseases and conditions, such as cardiac and neurological disorders, are limited by pharmacological efficacy and safety issues, including side effects from NA supplements and PARP inhibitors.
Innovation Solution
Development of small-molecule NAMPT activators, represented by compounds of specific Formulae, to increase NAD+ levels safely and effectively, as shown in compounds 1 to 645, which can be administered alone or with additional active pharmaceutical agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If nicotinic acid (NA) supplements are used to increase NAD+ levels, then NAD+ levels are improved, but cutaneous flushing occurs due to GPR109A activation
Solution Approach 1:
The patent introduces NAMPT activators as intermediary compounds that indirectly boost NAD+ levels by activating the NAMPT enzyme, rather than directly supplementing NA. This mediator approach achieves the desired NAD+ elevation without triggering GPR109A activation and subsequent cutaneous flushing.
Solution Approach 2:
The invention extracts the beneficial effect (NAD+ elevation) from the harmful pathway (GPR109A activation). By targeting NAMPT specifically, the patent separates the desired NAD+ boosting effect from the unwanted cutaneous flushing side effect that occurs with direct NA supplementation.
2Quantity of substance
If PARP inhibitors are prescribed to boost NAD+ levels, then NAD+ levels are improved, but side effects occur due to underlying toxicity
Solution Approach 1:
Instead of inhibiting PARP to indirectly increase NAD+ levels, the patent inverts the approach by directly activating NAMPT, the rate-limiting enzyme in NAD+ biosynthesis. This reverse strategy achieves NAD+ elevation through a safer, more direct pathway that avoids the toxicity associated with PARP inhibition.
Solution Approach 2:
The patent introduces NAMPT activators as a safer intermediary mechanism to boost NAD+ levels. Unlike PARP inhibitors that cause toxicity, these activators work through the natural NAMPT enzyme pathway, providing a non-toxic route to increase NAD+ levels.
3Adaptability or versatility
If existing NAMPT activators are used to boost NAD+ levels, then NAD+ levels are increased, but pharmacological efficacy and safety challenges remain
Solution Approach 1:
The patent optimizes key parameters of NAMPT activators including molecular structure, potency, selectivity, and pharmacokinetic properties. By systematically adjusting these parameters, the invention achieves compounds with improved efficacy, safety, and reliability for treating various diseases while maintaining broad therapeutic applicability.
Solution Approach 2:
The patent employs composite molecular structures combining specific chemical moieties (e.g., carbazole, indole, pyridine rings with various substituents) to create NAMPT activators with enhanced properties. These composite structures provide both high NAMPT activation potency and improved safety profiles for reliable therapeutic use.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds enhance NAD+ levels, providing therapeutic benefits for a range of diseases and conditions, including cardiac, renal, and neurological disorders, with improved safety and efficacy compared to existing approaches.
Implementation Method 1
NAMPT, a dimeric type II phosphoribosyl transferase, is a key enzyme in the dominant nicotinamide adenine dinucleotide (NAD+) metabolism pathway in humans. Specifically, NAMPT catalyzes the rate limiting reaction in this pathway to convert nicotinamide and phosphoribosyl pyrophosphate to an intermediate nicotinamide mononucleotide (NMN), which is subsequently converted to NAD.
Data Source
AI summary
This disclosure provides compounds of Formula 1 or 8, compositions comprising the same, and methods of using the same, including uses in modulating NAMPT and treating various diseases and conditions that are responsive to NAMPT activation.